123
Participants
Start Date
September 30, 2011
Primary Completion Date
February 28, 2013
Study Completion Date
February 28, 2013
Placebo
Tablets, Oral, 0 mg, twice daily, 12 weeks
BMS-817399
Tablets, Oral, 200 mg, twice daily, 12 weeks
BMS-817399
Tablets, Oral, 400mg, twice daily, 12 weeks
Local Institution, Buenos Aires
Local Institution, Capital Federal
Local Institution, Buenos Aires
Local Institution, San Miguel de Tucumán
Local Institution, Durban
Local Institution, Pinelands
Local Institution, Panorama
Local Institution, Córdoba
Local Institution, Santiago de Compostela
Altoona Center For Clinical Research, Duncansville
Local Institution, Tijuana
Sarasota Arthritis Research Center, Sarasota
Local Institution, Seville
Paramount Medical Research & Consulting, Llc, Middleburg Heights
Local Institution, Guadalajara
Local Institution, Guadalajara
Local Institution, Guadalajara
Local Institution, San Luis Potosí City
Desert Medical Advances, Palm Desert
Local Institution, Mérida
Local Institution, Moscow
Local Institution, Yaroslavl
Pharma Resource, East Providence
Local Institution, D.f.
Local Institution, Pretoria
Local Institution, Daegu
Local Institution, Gwangju
Local Institution, Seoul
Local Institution, Seoul
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY